In this project, we have reorganized several highly immunogenic sitesstructurally essential regions to maintain it in a pre-fusion stateuse it as main antigen in our RSV vaccine candidate (RSV-F005). To induce a mucosal immune response, intranasal administration route was chosen. New mucosal adjuvant (H-muad) has been tested in threee animal models.

Two COVID-19 animal models, including humanized Ace2 micehuman peripheral blood lymphocyte transplanted mice, are used to mimic COVID-19 infection, immune responsecytokine release syndrome in human. The immune analytical platform can further outline the immune cell, cytokinebiomarker response pattern after viral infection. The COVID-19 humanized animal modelthe immune analytical platform will support COVID-19 related researchfacilitate new drugnew therapy validation.

With the use of E. coli expression system, capsid protein assembly in vitro, X-ray photoprotein crystallographycryo-electron microscope, the T=3 capsid structure of white tail disease viruses for shrimps has been resolved successfully, such that an entire model for capsid structure of virus could be provideda mechanism for viral assemblyinfection could be understood.

Vaccination is the most effective way to prevent influenza viruses infection. The egg-based production method has many drawbacks, we established baculovirus-based VLPs expression platform for H7N9 VLPs production, purify the VLPs satisfied with FDA regulation,improved its immunogenicity to the same level compared with H7N9 whole virus vaccine.